



Science Report 2015

A collage of various scientific and medical-related images and logos. It includes: 'Clinical Advances in Diabetes Mellitus' by Thomas Forst & Christoph Kapitza; a coat of arms; the 'CLOSE' logo with a house icon; the 'eit Health' logo; the European Union flag; the '51st ANNUAL MEETING EASD 14-18 SEPTEMBER STOCKHOLM 2015'; a flowchart of the drug development process: 'Basic Research' -> 'Disease Discovery' -> 'Drug Discovery' -> 'Preclinical Development' -> 'Clinical Trials Phases I, II, III' -> 'Postmarketing surveillance'; 'nature medicine' logo; 'DIABETES, OBESITY AND METABOLISM A JOURNAL OF PHARMACOLOGY AND THERAPEUTICS'; 'The NEW ENGLAND JOURNAL of MEDICINE'; 'American Diabetes Association. 75th ANNIVERSARY scientificsessions JUNE 5-9, 2015 • BOSTON, MA'; 'CBmed BIOMARKER RESEARCH'; 'DuET 2015 Clinical Research and Trials in Diabetes'; 'WEBINARS Watch past webinars and register for our next session'; and 'Free Consultation' with a graduation cap icon.

www.profil.com

Content

Science Report 2015	1
Content	2
Metrics	3
Scientific Publications	4
Original Articles	5
Reviews.....	10
Letters / Comments	11
Book Chapter	12
Book.....	13
Scientific Presentations.....	14
Oral Presentations	14
Poster Presentations.....	19
Advanced Training Courses.....	26
Granted Research Projects.....	27
Scientific Communication.....	29
Webinars	29
Blogs	29
Newspaper Articles (Selection)	32

Metrics

TABLE 1: TOTAL OUTPUT

	Count	Σ Impact Factors	Mean Impact Factor
Scientific Publications	41	222,859	6,023
Original Articles	28	200,518	7,161
Reviews	7	5,501	0,786
Letters/Comments	2	16,840	8,420
Book Chapters	3	n/a	n/a
Books	1	n/a	n/a
Scientific Congress Presentations	86	n/a	n/a
Orals	39	n/a	n/a
Poster	47	n/a	n/a
Advanced Trainings	2	n/a	n/a
Granted Research Projects	6	n/a	n/a
Scientific Communication	37+	n/a	n/a
Webinars	4	n/a	n/a
Blogs	26	n/a	n/a
Newspaper	7+	n/a	n/a

TABLE 2: PROFIL SCIENTIST(S) FIRST/SENIOR AUTHOR/EDITOR

	Count	Σ Impact Factors	Mean Impact Factor
Scientific Publications	30	98,713	3,797
Original Articles	17	76,372	4,492
Reviews	7	5,501	0,786
Letters/Comments	2	16,840	8,420
Book Chapters	3	n/a	n/a
Books	1	n/a	n/a
Scientific Congress Presentations	71	n/a	n/a
Orals	33	n/a	n/a
Poster	38	n/a	n/a

TABLE 3: STUDIES (PARTLY) OPERATED BY PROFIL

	Count	Σ Impact Factors	Mean Impact Factor
Scientific Publications	23	178,452	7,759
Original Articles	23	178,452	7,759
Reviews	n/a	n/a	n/a
Letters/Comments	n/a	n/a	n/a
Book Chapters	n/a	n/a	n/a
Books	n/a	n/a	n/a
Scientific Congress Presentations	60	n/a	n/a
Orals	16	n/a	n/a
Poster	44	n/a	n/a

TABLE 4: STUDIES (PARTLY) OPERATED BY PROFIL
+ PROFIL SCIENTIST(S) FIRST/SENIOR AUTHOR

	Count	Σ Impact Factors	Mean Impact Factor
Scientific Publications	15	67,359	4,491
Original Articles	15	67,359	4,491
Reviews	n/a	n/a	n/a
Letters/Comments	n/a	n/a	n/a
Book Chapters	n/a	n/a	n/a
Books	n/a	n/a	n/a
Scientific Congress Presentations	48	n/a	n/a
Orals	11	n/a	n/a
Poster	37	n/a	n/a

Scientific Publications

Original Articles

1. Marquard, J., Otter, S., Welters, A., Stirban, A.¹, Fischer, A., Eglinger, J., Herebian, D., Kletke, O., Klemen, M.S., Stožer, A., Wnendt, S., Piemonti, L., Köhler, M., Ferrer, J., Thorens, B., Schliess, F., Rupnik, M.S., Heise, T., Berggren, P.O., Klöcker, N., Meissner, T., Mayatepek, E., Eberhard, D., Kragl, M., Lammert, E. Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment.
Nat. Med. 2(4): 363-372, 2015
IF(2014): 27.363
2. Thabit, H., Tauschmann, M., Allen, J.M., Leelarathna, L., Hartnell, S., Wilinska, M.E., Acerini, C.L., Dellweg, S., Benesch, C., Heinemann, L., Mader, J.K., Holzer, M., Kojzar, H., Exall, J., Yong, J., Pichierri, J., Barnard, K.D., Kollman, C., Cheng, P., Hindmarsh, P.C., Campbell, F.M., Arnolds, S., Pieber, T.R., Evans, M.L., Dunger, D.B., Hovorka, R.; APCam Consortium and AP@home Consortium. Home use of an artificial beta cell in type 1 diabetes
N. Engl. J. Med. PMID: 26379095, 2015
IF(2014): 55.873
3. Muscelli, E., Astiarraga, B., Barsotti, E., Mari, A., Schliess, F., Nosek, L., Heise, T., Broedl, U.C., Woerle, H.-J., Ferrannini, E. Metabolic consequences of acute and chronic empagliflozin administration in treatment-naïve and metformin pre-treated patients with type 2 diabetes.
Diabetologia, accepted for publication
IF(2014): 6.671
4. Heise, T., Bain, S.C., Bracken, R.M., Zijlstra, E., Nosek, L., Stender-Petersen, K., Rabøll, R., Rowe, E., Haahr, H.L. Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial.
Diabetes Obes. Metab. DOI: 10.1111/dom.12588, 2015
IF(2014): 6.360

¹ Underlined: authors from Profil Germany

5. Marquard, J., Stirban, A., Schliess, F., Sievers, F., Welters, A., Otter, S., Fischer, A., Wnendt, S., Meissner, T., Heise, T., Lammert, E.
Effects of dextromethorphan as add-on to sitagliptin on blood glucose and serum insulin concentrations in individuals with type 2 diabetes mellitus: a randomized, placebo-controlled, double-blinded, multiple crossover, single-dose clinical trial.
Diabetes Obes. Metab. doi: 10.1111/dom.12576, 2015
IF(2014): 6.360
6. Heise, T., Hövelmann, U., Nosek, L., Hermanski, L., Böttcher, S.G., Haahr, H.
Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Expert Opin. Drug Metab. Toxicol. 11(8): 1193-201, 2015
IF(2014): 2.831
7. Heise, T., Hövelmann, U., Brøndsted, L., Adrian, C.L., Nosek, L., Haahr, H.
Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart.
Diabetes Obes Metab. 17(7): 682-688, 2015
IF(2014): 6.360
8. Heise, T., Nosek, L., Klein, O., Coester, H.V., Svendsen, A.L., Haahr, H.
Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus.
Diabetes Obes. Metab. 17(7): 659-64, 2015
IF(2014): 6.360
9. Heise, T., Bain, S.C., Bracken, R.M., Zijlstra, E., Nosek, L., Stender-Petersen, K., Rabøl, R., Rowe, E., Haahr, H.L.
Similar risk of exercise-related hypoglycaemia for insulin degludec compared with insulin glargine in patients with type 1 diabetes: a randomised cross-over trial.
Diabetes Obes. Metab. doi: 10.1111/dom.12588, 2015
IF(2014): 6.360
10. Thabit, H., Leelarathna, L., Wilinska, M.E., Elleri, D., Allen, J.M., Lubina-Solomon, A., Walkinshaw, E., Stadler, M., Choudhary, P., Mader, J.K., Dellweg, S., Benesch, C., Pieber, T.R., Arnolds, S., Heller, S.R., Amiel, S.A., Dunger, D., Evans, M.L., Hovorka, R.
Accuracy of continuous glucose monitoring during three closed-loop home studies under free-living conditions.
Diabetes Technol. Ther. 17(11): 801-807, 2015
IF(2014): 2.106

11. Benesch, C., Heise, T., Klein, O., Heinemann, L., Arnolds, S.
How to assess the quality of glucose clamps? Evaluation of clamps performed with ClampArt, a novel automated Clamp Device.
J. Diabetes Sci. Technol. 9(4): 792-800, 2015
IF(2014): -

12. Boronikolos, G.C., Menge, B.A., Schenker, N., Breuer, T.G., Otte, J.M., Heckermann, S., Schliess, F., Meier, J.J.
Upper gastrointestinal motility and symptoms in individuals with diabetes, prediabetes and normal glucose tolerance.
Diabetologia 58(6): 1175-1182, 2015
IF(2014): 6.671

13. Arnolds, S., Heckermann, S., Heise, T., Sawicki, P.T.
Spectrum of diabetes research does not reflect patients' scientific preferences: a longitudinal evaluation of diabetes research areas 2010-2013 vs. a cross-sectional survey in patients with diabetes.
Exp. Clin. Endocrinol. Diabetes 123(5): 299-302, 2015
IF(2014): 1.555

14. Heise, T., Mattheus, M., Woerle, H.J., Broedl, U.C., Macha, S.
Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study.
Clin. Ther. 37(4): 793-803, 2015
IF(2014): 2.731

15. Heise, T., Korsatko, S., Nosek, L., Coester, H.V., Deller, S., Roepstorff, C., Segel, S., Kapur, R., Haahr, H., Hompesch, M.
Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action.
J. Diabetes Jan 12. doi: 10.1111/1753-0407.12266, 2015
IF(2014): 1.932

16. Blauw, H., Wendl, I., DeVries, J.H., Heise, T., Jax, T.; PCDIAB consortium.
Pharmacokinetics and pharmacodynamics of various glucagon dosages at different blood glucose levels.
Diabetes Obes. Metab., doi: 10.1111/dom.12571, 2015
IF(2014): 6.360

17. Shiramoto, M., Eto, T., Irie, S., Fukuzaki, A., Teichert, L., Tillner, J., Takahashi, Y., Koyama, M., Dahmen, R., Heise, T., Becker, R.H.
Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes.
Diabetes Obes. Metab. 17(3): 254-260, 2015
IF(2014): 6.360

18. Becker, R.H., Dahmen, R., Bergmann, K., Lehmann, A., Jax, T., Heise, T.
New insulin glargine 300 Units · mL⁻¹ provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL⁻¹.
Diabetes Care 38(4): 637-643, 2015
IF(2014): 8.420
19. Forst, T., Michelson, G., Diessel, S., Jahnke, J., Kapitza C.
Microvascular effects of the inhibition of dipeptidylpeptidase IV by linagliptin in nondiabetic hypertensive patients.
J. Hypertens. epub ahead of print, 2015
IF(2014): 4.720
20. Rini, C.J., McVey, E., Sutter, D., Keith, S., Kurth, H.J., Nosek, L., Kapitza, C., Rebrin, K., Hirsch, L., Pettis, R.J.
Intradermal insulin infusion achieves faster insulin action than subcutaneous infusion for 3-day wear.
Drug Deliv. Transl. Res. 5(4): 332-45, 2015
IF(2014): -
21. Kapitza, C., Bode, B., Ingwersen, S.H., Jacobsen, L.V., Poulsen, P.
Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy.
J. Clin. Pharmacol. doi: 10.1002/jcph.549, 2015
IF(2014): 2.475
22. Meier, J.J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.V., Menge, B.A., Forst, T., Kapitza, C.
Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial.
Diabetes Care 38(7): 1263-73.
IF(2014): 8.420
23. Kapitza, C., Nosek, L., Jensen, L., Hartvig, H., Jensen, C.B., Flint, A.
Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel.
J. Clin. Pharmacol. 55(5): 497-504, 2015
IF(2014): 2.475
24. Becker, R.H., Nowotny, I., Teichert, L., Bergmann, K., Kapitza, C.
Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.
Diabetes Obes. Metab. 17(3): 261-267, 2015
IF(2014): 6.360

25. Sha, S., Polidori, D., Farrell, K., Ghosh, A., Natarajan, J., Vaccaro, N., Pinheiro, J., Rothenberg, P., Plum-Mörschel, L.
Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.
Diabetes Obes. Metab. 17(2): 188-197, 2015
IF(2014): 6.360
26. Leiter, L.A., Forst, T., Polidori, D., Balis, D.A., Xie, J., Sha, S.
Effect of canagliflozin on liver function tests in patients with type 2 diabetes.
Diabetes Metab. doi: 10.1016/j.diabet.2015.10.003, 2015
IF(2014): 3.267
27. Grunberger, G., Forst, T., Fernández Landó, L., Pechtner, V., Shaginian, R., Jia, N., Gough, S.
Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide.
Diabet. Med. DOI: 10.1111/dme.12833, 2015
IF(2014): 3.115
28. Forst, T., Koch, C., Dworak, M.
Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week study.
Curr. Med. Res. Opin. 31(6): 1079-84, 2015
IF(2014): 2.653

Reviews

29. Heer, M., Egert, S.
Nutrients other than carbohydrates: their effects on glucose homeostasis in humans.
Diabetes Metab. Res. Rev. 31(1): 14-35, 2015
IF(2014): 3.553
30. Stirban, A., Tschöpe, D.
Vascular effects of dietary advanced glycation end products.
Int. J. Endocrinol. doi: 10.1155/2015/836498, 2015
IF(2014): 1.948
31. Forst, T.
Neue Insuline: das hat der Markt zu bieten.
Diabetes Forum 9: 21-27, 2015
IF(2014): -
32. Forst, T.
Diabetes Medikamente 2015.
Diabetes Journal 10: 16-23, 2015
IF(2014): -
33. Forst, T., Arnolds, S., Jahnke, J.
Orale Antidiabetika: Übersicht 2015.
Diabetes Journal 10: 24, 2015
IF(2014): -
34. Arnolds S.
Therapie undenkbar ohne Schulung.
Diabetes Journal 10: 30-31, 2015.
IF(2014): -
35. Forst, T.
Das Raubtier braucht viel Aufmerksamkeit. Diabetische Polyneuropathie.
INFO Diabetologie 9(3): 36-43, 2015
IF(2014): -

Letters / Comments


36. Arnolds, S., Sawicki, P.T.
Comment on Retnakaran et al. Liraglutide and the preservation of pancreatic β -cell function in early type 2 diabetes: the LIBRA trial. *Diabetes Care* 2014;37:3270-3278.
Diabetes Care 38(2): e25. doi: 10.2337/dc14-2418, 2015
IF(2014): 8.420
37. Heinemann, L., Zijlstra, E., Pleus, S., Freckmann, G.
Performance of blood glucose meters in the hypoglycemic range: current evaluations indicate that this is not sufficient from a clinical point of view.
Diabetes Care 38: e139-e140, 2015
IF(2014): 8.420

Book Chapter

38. Forst, T., Kapitza, C.
Clinical advances in diabetes mellitus.
In "Clinical advances in diabetes mellitus".
Editors: T. Forst, C. Kapitza.
Future Science Ltd, London, UK, p. 3-6, 2015
39. Forst, T., Theodor, R., Weber, M.
Pathophysiology of type 2 diabetes mellitus & vascular disease.
In "Clinical advances in diabetes mellitus".
Editors: T. Forst, C. Kapitza.
Future Science Ltd, London, UK, p. 19-34, 2015
40. Stirban, A.
Peripheral neuropathy in diabetes mellitus.
In "Clinical advances in diabetes mellitus".
Editors: T. Forst, C. Kapitza.
Future Science Ltd, London, UK, p. 75-92, 2015

Book

41. Forst, T., Kapitza, C. (eds.)
Clinical advances in diabetes mellitus.
Future Science Ltd, London, 2015



Scientific Presentations

Oral Presentations

Diabetes Schwerpunktpraxen. Düsseldorf, Germany, December 7, 2015

42. Arnolds, S.
Patienteninitiierte Forschung.

IDF 2015 Vancouver World Diabetes Congress. Vancouver, Canada, November 30 – December 4, 2015

43. Heise, T., Philis-Tsimikas, A.
What is new in insulin treatment?
Symposium Novo Nordisk A/S
44. Forst, T.
Basic and clinical science: SGLT-2 inhibitors.
Webcast

44. Jahrestagung der Österreichischen Diabetes Gesellschaft. Salzburg, Austria, November 17 – 19, 2015

45. Forst, T.
Wie zeitgemäß sind Sulfonylharnstoffe?

Herbsttagung der Arbeitsgemeinschaft Diabetologie und Endokrinologie Rheinland Pfalz e.V.. Mainz, Germany, November 14, 2015

46. Zijlstra, E.
Klinische Bedeutung und Interpretation der kontinuierlichen Glukosemessung.

9. Herbsttagung der Deutschen Diabetes Gesellschaft. Düsseldorf, Germany, November 6 – 7, 2015

47. Zijlstra, E.
Senseonics implantierbares CGM: Erfahrungen der deutschen Patienten in der
PRECISE Studie.
Symposium der Roche Diagnostics Deutschland GmbH

48. Forst, T.
Stellenwert des langwirksamen Insulin-Analogons Abasaglar® in der Therapie des Typ 2 Diabetes.
Symposium der Boehringer Ingelheim Pharma GmbH & Co. KG and Lilly Deutschland GmbH
49. Forst, T.
Sicherheitsrelevante Daten zu Sulfonylharnstoffen: etablierte oder riskante Therapie?
DDG Symposium
50. Heinemann, L.
Einfluss von Lipohypertrophien auf die Insulinabsorption: Was ist dazu bekannt?
Industriesymposium
51. Heinemann, L.
Lipohypertrophien – welche Bedeutung haben diese für die Praxis?
WinDiab Symposium

15. Annual Diabetes Technology Meeting. Bethesda, Maryland, USA, October, 22 – 24, 2015

52. Heise, T.
Variability of insulin absorption.
S34, 2015; **J. Diabetes Science Technology**, March 2016
53. Kropff, J., Choudhary, P., Hovorka, R., Bain, S.C., Kapitza, C., Forst, T., Link, M., DeVries, J.H.
Accuracy and longevity of an implantable continuous glucose sensor in the Precise study: a prospective multi-center pivotal trial.
S41, 2015; **J. Diabetes Science Technology**, March 2016

2. Heidelberg International Symposium on Diabetic Complications. October 16 – 17, 2015

54. Lammert, E. NMDA receptors – novel drug targets for diabetes treatment.

**Gulf Chapter of the American Association of Clinical Endocrinologists.
Dubai, Abu Dhabi, October 15 – 17, 2015**

55. Forst, T.
Effectiveness and safety profile of dulaglutide.
56. Forst, T.
Non-glycemic of GLP-1 agonists: obesity – cardiovascular protection – hypertension – endothelial effect – renal protection.

51. EASD Annual Meeting. Stockholm, Sweden, September 14 – 18, 2015

57. Lam, E.C.Q., Garhyan, P., Linnebjerg, H., Choi, S.L., Knadler, M.P., Sinha, V.P., Sassenfeld, B.M., Nosek, L., Heise, T.
Reduced intra-subject variability of basal insulin peglispro (BIL) compared with insulin glargine (GL) in patients with type 1 diabetes mellitus (T1DM).
Diabetologia 58 (Suppl. 1): S1, 2015
58. Pieber, T.R., Famulla, S., Eilbracht, J., Cescutti, J., Soleymanlou, N., Johansen, O., Woerle, H.-J., Broedl, U.C., Kaspers, S.
Empagliflozin reduces HbA1c with lower insulin doses in patients with type 1 diabetes: a 4-week placebo-controlled trial (EASE-1)
Diabetologia 58 (Suppl. 1): A181, 2015
59. Heise, T., Sorli, C.
What is new in insulin treatment?
Symposium Novo Nordisk A/S

Trulicity Launch. Bern, Switzerland, June 25, 2015

60. Forst, T.
Dulaglutide – designed with the patient in mind.

ADA 75th Scientific Sessions. San Francisco, CA, June 5 – 9, 2015

61. Lam, E.C.Q., Garhyan, P., Linnebjerg, H., Choi, S.L., Knadler, M.P., Sinha, V.P., Sassenfeld, B.M., Nosek, L., Heise, T.
Reduced intra-subject variability of basal insulin peglispro (BIL) compared with Insulin glargine (GL) in patients with type 1 diabetes mellitus (T1DM).
Diabetes 64 (Suppl. 1): 94-OR, 2015
62. Meier, J.J., Menge, B., Schenker, N., Schliess, F., Kapitza, C.
Mechanisms of action of the glucose-lowering effect of lixisenatide in combination with insulin glargine.
Diabetes 64 (Suppl. 1): 281-OR

Regional Innovation Network Diabetes. Düsseldorf, Germany, May 27, 2015

63. Arnolds, S.
Patienteninitiierte Forschung – welche Forschung wünschen sich Patienten mit Diabetes?

50. Jahrestagung der Deutschen Diabetes Gesellschaft. Berlin, Germany, May 13 – 16, 2015

64. Arnolds, S.
Welche Forschung wünschen sich Patienten mit Diabetes?
winDiab – Personalisierte Therapie

- 65. Heinemann, L.
Closed-Loop im Alltag: die Zukunft ist (fast) da.
winDiab – Personalisierte Therapie
- 66. Heinemann, L.
Was ist heute realistisch, was gibt es an neuen Therapieformen?
Update-Sitzung: Diabetes und Realität bei Kindern und Jugendlichen
- 67. Hahnefeld, M., Forst, T.
Zwischen guter Blutzuckereinstellung und Vermeidung von Hypoglykämien.
Industriesymposium der Sanofi-Aventis Deutschland GmbH
- 68. Forst, T.
Ein neuer GLP-1 Agonist im Spektrum der antidiabetischen Therapie.
Industriesymposium der Lilly Deutschland GmbH

Middle East Diabetes Summit Dubai. Dubai, Abu Dhabi, May 1, 2015

- 69. Forst, T.
Does Pre-Mix Insulin have an advantage over basal insulin in Invitation of therapy.
Debate
- 70. Forst, T.
Dulaglutide – new aera in GLP1 RAs (UAE only) - introduction to biosimilars.

26. National Congress Spanish Society of Diabetes. Valencia, Spain, April 16 – 18, 2015

- 71. Lammert, E.
Role of NMDA receptors as drug targets for future diabetes treatment.

Diabetiker Selbsthilfegruppe. Hilden, April 13, 2015

- 72. Arnolds, S.
Was gibt es Neues aus der Diabetesforschung?

Trulicity Mega Launch Meeting. Dubai, Abu Dhabi, March 27 – 28, 2015

- 73. Forst, T.
Trulicity - a once-weekly glucagen-like peptide-1 receptor agonist in a ready-to-use pen.

Slovenian National Diabetology Conference. Ljubljana, Slovenia, March 14, 2015

- 74. Forst, T.
GLP-1 receptor agonists.

Advanced Technologies and Treatments for Diabetes. Paris, France, February 18 – 21, 2015

75. Zijlstra, E.
Inhaled insulin reloaded: impact of Afrezza®.
Diabetes Technol. Ther. 17(S1): A-6
76. Heise, T.
Oral insulin – what’s going on?
Diabetes Technol. Ther. 17(S1): A-6
77. Heise, T., Haahr, H., Jensen, L., Erichsen, L., Hompesch, M.
Faster-acting insulin aspart improves postprandial glycaemia versus insulin aspart in patients with type 1 diabetes mellitus.
Diabetes Technol. Ther. 17(S1): A-4

Karolinska Institute. Stockholm, Sweden, February 12, 2015

78. Lammert, E.
Characterisation of pancreatic NMDA receptors as possible drug targets for diabetes. treatment

Jointed congress: 30. Danube Symposium / 10. Congress of the Central European Diabetes Society / 10. Annual Meeting of the North-Rhine Westphalian Society for Endocrinology and Diabetology. Düsseldorf, Germany, February 5 – 7, 2015

79. Lammert, E.
Therapies targeting pancreatic islets.

Kirchheim-Forum Diabetes. Berlin, Germany, February 5 – 7, 2015

80. Forst, T.
Neue Insuline und inhalatives Insulin.

Poster Presentations

IDF 2015 Vancouver World Diabetes Congress. Vancouver, Canada, November 30 – December 4, 2015

81. Heise, T., Zijlstra, E., Rikte, T., Thorsson, L., Nosek, L., Haahr, H.
Faster-acting insulin aspart by CSII: Earlier exposure and greater early PK / PD effects than insulin aspart.
0396-PD, 2015
82. Hövelmann, U., Zijlstra, E., Stender-Petersen, K., Jacobsen, J.B., Heise, T., Haahr, H.
Faster aspart: Greater early exposure and action vs insulin aspart in elderly and younger adults with T1D.
0358P, 2015

15. Annual Diabetes Technology Meeting. Bethesda, Maryland, USA, October 22 – 24, 2015

83. Zijlstra, E., Heise, T., Nosek, L., Coester, H.V., Lückemeyer, K., Porter, L., Miller, S., Vick, A., Fink, J., Patton, J.
Particle size does not impact the pharmacokinetic response of a novel inhaled human insulin.
A129, 2015; **J. Diabetes Science Technology**, March 2016
84. Zijlstra, E., Heise, T., Nosek, L., Coester, H.V., Lückemeyer, K., Porter, L., Miller, S., Vick, A., Fink, J., Patton, J.
Dance-501 inhaled human insulin has a dose-linear response and similar within subject variability as rapid-acting insulin lispro.
A130, 2015; **J. Diabetes Science Technology**, March 2016
85. Zijlstra, E., Rastogi, R., Rasoni, B. Choudhary, P.
Demonstration of very high compliance and HbA1c benefit of a long-term implantable glucose sensor in the PRECISE study.
A132, 2015; **J. Diabetes Science Technology**, March 2016
86. Zijlstra, E., Heise, T., Rikte, T., Thorsson, L., Nosek, L., Haahr, H.
Faster-acting insulin aspart using continuous subcutaneous insulin infusion (CSII): earlier onset of exposure and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart.
A131, 2015; **J. Diabetes Science Technology**, March 2016
87. Carlson, G., Chen, X., Mdingi, C., Dehennis, A., Zijlstra, E.
Safety analysis of a 90-day implantable CGM system.
A13, 2015; **J. Diabetes Science Technology**, March 2016

88. Famulla, S., Heise, T., Kronshage, B., Zaher, T.S.A., Hövelmann, U.
The recombinant human soluble insulin Julphar insulin R is bioequivalent to Huminsulin Normal, an EU marketed soluble insulin.
A27, 2015; **J. Diabetes Science Technology**, March 2016
89. Benesch, C., Kuhlenkötter, M., Heise, T.
ClampArt: improved algorithm for automated glucose clamps.
A8, 2015; **J. Diabetes Science Technology**, March 2016
90. Reiterer, F., Polterauer, P., Schrangl, P., Heinemann, L., Freckmann, G., del Re, L.
Is there a recipe for comparability of mean absolute relative difference values from clinical performance evaluation of continuous glucose monitoring sensors?
A83, 2015; **J. Diabetes Science Technology**, March 2016

51. EASD Annual Meeting. Stockholm, Sweden, September, 14 – 18

91. Linnebjerg, H., Lam, E., Choi, S., Knadler, M.P., Porksen, N., Sinha, V.P., Garhyan, P., Klein, O., Nosek, L., Heise, T.
Effect of exercise on pharmacokinetics (PK) of basal insulin peglispro (BIL) and insulin glargine (GL) in type 1 diabetes mellitus patients.
Diabetologia 58 (Suppl. 1): S164, 2015
92. Kaspers, S., Famulla, S., Pieber, T.R., Eilbracht, J., Neubacher, D., Soleymanlou, N., Broedl, U.C.
Dapagliflozin decreases glucose exposure and variability in patients with type 1 diabetes: continuous glucose monitoring data.
Diabetologia 58 (Suppl. 1): S367, 2015
93. Zijlstra, E., Heise, T., Rikte, T., Thorsson, L., Nosek, L., Haahr, H.
Faster-acting insulin aspart by continuous subcutaneous insulin infusion: earlier exposure and greater early pharmacokinetic / pharmacodynamic effects vs insulin aspart.
Diabetologia 58 (Suppl. 1): S452, 2015
94. Forst, T., Rohwedder, K., Johnsson E.
Dapagliflozin decreases post-prandial glucose without an increase in C-peptide or insulin.
Diabetologia 58 (Suppl. 1): S349, 2015
95. Thabit, H., Leelarathna, L., Dellweg, S., Mader, J.K., Hanrtnell, S., Benesch, C., Kojzar, H., Holzer, M., Heinemann, L., Wiliniska, M., Pieber, T.R., Arnolds, S., Evans, M.L., Hovorka, R., on behalf of AP@home consortium.
Twelve-week unsupervised day-and-night closed loop insulin delivery during free daily in adults with type 1 diabetes: a multicenter randomized crossover study.
Diabetologia 58 (Suppl. 1): S478, 2015

96. Jax, T., von Eynatten, M., Stirban, A., Terjung, A., Esmaeli, H., Berk, A., Thiemann, S., Chilton, R., Marx, N.
A randomized, active- and placebo-controlled, three period crossover trial to investigate short-term effects of linagliptin on endothelial function in type 2 diabetes.
Diabetologia 58 (Suppl. 1): S390-S391, 2015
97. Hirsch, L., Hövelmann, U., Famulla, S., Hermanski, L., Fischer, A., Heinemann, L., Kalthener, M., Heise, T.
Insulin injection into regions with lipohypertrophy worsens postprandial blood glucose versus injections into normal adipose tissue.
Diabetologia 58 (Suppl. 1): S439, 2015
98. Famulla, S., Hövelmann, U., Fischer, A., Coester, H.V., Heinemann, L., Kalthener, M., Hirsch, L., Heise, T.
Lipohypertrophy leads to blunted, more variable insulin absorption and action in patients with type 1 diabetes.
Diabetologia 58 (Suppl. 1): S439-S440, 2015
99. Andersen, G., Alluis, B., Meiffren, G., Ranson, A. Seroussi, C., Gaudier, M., Soula, O., Fischer, A., Nosek, L., Heise, T.
Ultra-rapid BioChaperone insulin Lispro (BC-LIS): linear dose-response and faster absorption than insulin Lispro (LIS).
Diabetologia 58 (Suppl. 1): S449, 2015
100. Hövelmann, U., Zijlstra, E., Stender-Petersen, K., Jacobsen, J.B., Heise, T., Haahr, H.
Higher early insulin exposure and greater early glucose-lowering effect with faster-acting insulin aspart vs insulin aspart in elderly and younger adults with type 1 diabetes.
Diabetologia 58 (Suppl. 1): S450, 2015
101. Kapitza, C., Nowotny, I., Lehmann, A., Khatami, H., Bergmann, K., Rotthäuser, B., Becker, R.H.
Rapid-acting insulin lispro products SAR342434 and US- and EU-approved insulin lispro solution show similar pharmacokinetics and pharmacodynamics in subjects with type 1 diabetes mellitus.
Diabetologia 58 (Suppl. 1): S452-S453, 2015
102. Heise, T., Kapitza, C., Nosek, L., Lam, E., Choi, S., Garhyan, P., Jacober, S.J., Porsen, N., Prince, M.J., Linnebjerg, H.
Similar counter-regulatory hormone responses to hypoglycaemia with basal insulin peglispro (BIL) versus insulin Glargine (GL) in type 1 diabetes.
Diabetologia 58 (Suppl. 1): S466, 2015

ADA 75th Scientific Sessions. Boston, MA, June, 5 – 9, 2015

103. Zijlstra, E., Heise, T., Nosek, L., Coester, H.V., Lückemeyer, K., Porter, L., Miller, S., Vick, A., Fink, J.B., Patton, J.
Dance-501 inhaled human insulin has a dose-linear response and similar within-subject variability as rapid-acting insulin lispro.
Diabetes 64 (Suppl. 1): 978-P, 2015
104. Andersen, G., Alluis, B., Meiffren, G., Ranson, A., Seroussi, C., Gaudier, M., Soula, O., Fischer, A., Nosek, L., Heise, T.
Ultra-rapid BioChaperone insulin lispro (BC LIS): linear dose-response and faster absorption than insulin lispro (LIS).
Diabetes 64 (Suppl. 1): 979-P, 2015
105. Heise, T., Kapitza, C., Nosek, L., Lam, E.C.Q., Choi, S.L., Garhyan, P., Jacober, S.J., Porksen, N., Prince, M.J., Linnebjerg, H.
Similar counterregulatory hormone responses to hypoglycemia with basal insulin peglispro (BIL) vs. insulin glargine (GL) in type 1 diabetes.
Diabetes 64 (Suppl.1): 993-P, 2015
106. Linnebjerg, H., Lam, E.C.Q., Choi, S.L., Knadler, M.P., Porksen, N., Sinha, V.P., Garhyan, P., Klein, O., Nosek, L., Heise, T.
Effect of exercise on pharmacokinetics (PK) of basal insulin peglispro (BIL) and insulin glargine (GL) in type 1 diabetes mellitus (T1DM) patients.
Diabetes 64 (Suppl. 1): 996-P, 2015
107. Hövelmann, U., Famulla, S., Hermanski, L., Fischer, A., Heinemann, L., Kalthener, M., Hirsch, L., Heise T.
Insulin injection into regions with lipohypertrophy (LHT) worsens postprandial (PP) blood glucose (BG) vs. injections into normal adipose tissue (NAT).
Diabetes 64 (Suppl. 1): 1000-P, 2015
108. Heise, T., Zijlstra, E., Rikte, T., Thorsson, L., Nosek, L., Haahr, H.
Faster-acting insulin aspart using continuous subcutaneous insulin infusion (CSII): earlier onset of exposure and greater early pharmacokinetic (PK) and pharmacodynamic (PD) effects than insulin aspart.
Diabetes 64 (Suppl. 1): 1005-P, 2015
109. Famulla, S., Hövelmann, U., Fischer, A., Coester, H.V., Heinemann, L., Kalthener, L., Hirsch, L., Heise, T.
Lipohypertrophy (LHT) leads to blunted, more variable insulin absorption and action in patients with type 1 diabetes (T1DM).
Diabetes 64 (Suppl. 1): 1019-P, 2015

110. Nowotny, I., Kapitza, C., Lehmann, A., Khatami, H., Bergmann, K., Rotthaeuser, B., Becker, R.H.
Comparative PK and PD of the rapid-acting insulin lispro product SAR342434, and the U.S.- and EU-approved Humalog® in subjects with T1DM.
Diabetes 64 (Suppl. 1), 1022-P, 2015
111. Zijlstra, E., Heise, T., Nosek, L., Coester, H.V., Lückemeyer, K., Porter, L., Miller, S., Vick, A., Fink, J.B., Patton, J.
Particle size does not impact the pharmacokinetic response of a novel inhaled human insulin.
Diabetes 64 (Suppl. 1), 1028-P, 2015
112. Pieber, T.R., Famulla, S., Eilbracht, J., Cesutti, J., Solemanlou, N., Johansen, O.E., Woerle, H.-J., Broedl, U., Kaspers, S.
Empagliflozin (EMPA) reduces HbA1c with lower insulin doses in patients with type 1 diabetes (T1DM): a 4-week placebo-controlled trial (EASE-1).
Diabetes 64 (Suppl. 1), 1028-P, 2015
113. Famulla, S., Pieber, T.R., Eilbracht, J., Neubacher, D., Solemaymanlou, N., Woerle, H.-J., Broedl, U.C., Kaspers, S.
Empagliflozin decreases glucose exposure and variability in patients with type 1 diabetes (T1DM): continuous glucose monitoring (CGM) data (EASE-1).
Diabetes 64 (Suppl. 1), 1241-P, 2015
114. Forst, T., Rohwedder, K., Sugg, J., Johnsson, E.
Dapagliflozin decreases postprandial glucose without an increase in C-peptide or insulin
Diabetes 64 (Suppl. 1), 1249-P, 2015
115. Leiter, L.A., Forst, T., Polidori, D., Balis, D., Xie, J., Sha, S.
Changes in liver function tests (LFTs) with canagliflozin (CANA) vs. sitagliptin (SITA) in patients with type 2 diabetes mellitus (T2DM) are related to changes in A1C and body weight (BW)
Diabetes 64 (Suppl. 1), 1265-P, 2015
116. Forst, T., Michelson, G., Diessel, S., Jahnke, J., Kapitza, C.
Linagliptin improves retinal endothelial function and blood flow in nondiabetic, hypertensive subjects.
Diabetes 64 (Suppl. 1), 1302-P, 2015
117. Jordan, J., Stinkens, R., Jax, T., Engeli, S., Blaak, E., May, M., Havekes, B., Schindler, C., Albrecht, D., Pal, P., Heise, T., Goossens, G., Langenickel, T.
Metabolic benefits of LCZ696: a randomized, double-blind, active-controlled, parallel-group study in obese hypertensive patients.
Diabetes 64 (Suppl. 1), 2250-P, 2015

118. Marquard, J., Stirban, A., Schliess, F., Sievers, F., Welters, A., Otter, S., Fischer, A., Wnendt, S., Meissner, T., Heise, T., Lammert, E.
Effects of Dextromethorphan (DXM) alone and as add-on to sitagliptin (SITA) on blood glucose (BG) and serum Insulin (INS) concentrations in patients with type 2 diabetes mellitus (T2DM) after an oral glucose tolerance test (OGTT).
121-LB, 2015

50. Jahrestagung der Deutschen Diabetes Gesellschaft. Berlin, Germany, May 13 – 16, 2015

119. Zijlstra, E., Heinemann, L., Fischer, A., Kapitza, C.
Eine neue 3-Stufen Glukose-Clamp Methode zur Evaluierung von Blutzucker-messgeräten.
Diabetes & Stoffwechsel 10: S44, 2015
120. Zijlstra, E., Baumstark, A., Haug, C., Heinemann, L., Freckmann, G., Kapitza, C.
Leistung eines Blutzuckermessgerätes: Vergleich zwischen zwei Testverfahren.
Diabetes & Stoffwechsel 10: S44, 2015
121. Becker, R., Nowotny, I., Teichert, L., Bergmann, K., Kapitza, C.
Reproduzierbar schwankungsarme Blutspiegel beim neuen Insulin Glargin 300 E/mL.
Diabetes & Stoffwechsel 10: S64, 2015
122. Forst, T., Gough, S., Grunberger, G., Pechtner, V., Shaginian, R., Wang, H., Fernandez, L.
The 2 week fasting blood glucose (FBG) level as a predictor of HbA1c treatment response (HbA1c-TR) to once weekly dulaglutide 1.5 mg in patients with type 2 diabetes (T2DM).
Diabetes & Stoffwechsel 10: S69, 2015

Advanced Technologies and Treatments for Diabetes. Paris, France, February 18 – 21, 2015

123. Haahr, H., Hövelmann, U., Brøndsted, L., Adrian, C.L., Nosek, L., Heise, T.
Higher early insulin exposure and greater early glucose-lowering effect with faster-acting insulin aspart in patients with type 1 diabetes mellitus.
Diabetes Technol. Ther. 17(S1): A-41, 2015
124. Zijlstra, E., Heinemann, L., Fischer, A., Kapitza, C.
A new 3-step clamp method for the evaluation of blood glucose meters.
Diabetes Technol. Ther. 17(S1): A-93, 2015
125. Zijlstra, E., Baumstark, A., Haug, C., Heinemann, L., Freckmann, G., Kapitza, C.
Blood glucose meter performance: a comparison between two test procedures.
Diabetes Technol. Ther. 17(S1): A-94, 2015

126. Ruan, Y., Benesch, C., Zijstra, E., Hovorka, R.
Modelling glucose kinetics during euglycaemic clamp following administration of rapid acting insulin analogue.
Diabetes Technol. Ther. 17(S1): A-161, 2015
127. Haahr, H., Hövelmann, U., Brøndsted, L., Adrian, C.L., Nosek, L., Heise, T.
Higher early insulin exposure and greater early glucose-lowering effect with faster-acting insulin aspart in patients with type 1 diabetes mellitus.
Diabetes Technol. Ther. 17(S1): A-41, 2015

Advanced Training Courses

128. **Profil – Glucose-Clamp-Technique Introduction Course.**

November 4 – 5, 2015
Profil, Neuss, Germany
Sanofi – Aventis

129. **DuET 2015 Düsseldorf Education on Trials.**

November 25 – 26, 2015
Profil, Neuss, Germany
Novo Nordisk, Region Europe A/S

DuET 2015

**Clinical Research and
Trials in Diabetes**



Granted Research Projects

130. EIT-Health e.V. and German EIT Health GmbH.

A knowledge and innovation community (KIC) on healthy living and active ageing. Funded by the European Institute of Innovation and Technology (EIT)
 First funding period: 2015 – 2022
<http://eithealth.eu/>

Profil Neuss is EIT Health core partner and part of the European EIT Health e.V. partner assembly and the German EIT Health GmbH supervisory board.

EIT Health innovation project by design:
 Automated glucose control at home for people with chronic disease (CLOSE)
 Funding period: July 2016 – June 2020

Profil Neuss will be coordinating the CLOSE project.



The CLOSE consortium.

Air Liquide Santé International (France), Institute for Applied Quality Improvement and Research in Health Care GmbH (Germany), Ericpol Sp. z o. o. (Poland), European Research and Project Office GmbH (Germany), IESE Business School (Spain), Johannes Kepler University Linz (Austria), Katholieke Universiteit Leuven (Belgium), Medical University of Lodz (Poland), Profil GmbH (Germany), Novo Nordisk A/S (Denmark), Roche Diagnostics GmbH (Germany).

131. **Competence Center for Biomarker Research in Medicine.**

COMET K1 Center for Biomarker Research at CBmed
Funded by the Austrian Research Promotion Agency
First funding period: 2015 – 2019
<http://www.cbmed.org/en/index.php>

Profil Neuss is chairing the consortium board of the CBmed GmbH.

Profil Neuss is part of the project area “Metabolism & inflammation”
Project 3.6
Minimally invasive biomarkers for liver function.
Funding period: June 2015 – December 2018

132. **Regionales Innovationsnetzwerk (RIN) Diabetes.**

Funding: Ministerium für Innovation, Wissenschaft und Forschung des Landes
Nordrhein Westfalen.
Funding period: 2014 - 2017
<http://www.rin-diabetes.de/>

133. **SPIDIMAN – Single-Port Insulin Infusion for Improved Diabetes Management.**

EU Project 7th Framework Programme, contract no. 305343
European Project to Combine Glucose Monitoring and Insulin Infusion in a Single
Needle.
November 2012 – December 2016
<http://www.spidiman.eu/>

134. **MICROLOOP – Closed-loop glucose control in the hospital.**

BMBF SME-innovation: Medical Technology Funding Programme, MED-327-060
German Project to Develop a Medical Device for Glucose Control in the Hospital
October 2012 – September 2015

135. **PCDIAB – Portable bihormonal artificial pancreas.**

EU Project 7th Framework Programme, contract no. 305654
European Project to bring a portable bihormonal artificial pancreas to the patients’
home.
September 2012 – August 2015
<http://www.PCDIAB.eu/project>

Scientific Communication

Webinars

<http://www.profil.com/knowledge-center/webinars>

136. **Biosimilar insulin development.**
T. Forst, November 26, 2015
137. **ClampArt: next generation glucose clamps.**
T. Heise, September 7, 2015
138. **Diabetes: novel pathways – future treatments.**
T. Forst, July 14, 2015
139. **Alternative routes of insulin administration.**
E. Zijlstra, May 13, 2015

Blogs

<http://eithealth.eu/category/blog/>

140. **New treatment for diabetes, new paradigm for development.**
F. Schliess, December 1, 2015

<http://blog.profil.com/blog>

141. **Update on the new clinical trial regulations - pilot project of for new clinical trials regulation in Germany started.**
G. Andersen, November 23, 2015
142. **Clinical development of insulin biosimilars – approval process for biosimilar insulin.**
T. Forst, November 16, 2015
143. **Open innovation: what's going on in the healthcare sector?**
F. Schliess, November 2, 2015
144. **Open innovation: what is it and how does it work?**
F. Schliess, October 16, 2015

145. **The longest at-home free-living closed-loop study so far! International trial shows that 12-week day-and-night unsupervised use of an artificial pancreas system is feasible in adults with type 1 diabetes.**
S. Arnolds, September 18, 2015
146. **The islet of Langerhans - a pathophysiological approach in the treatment of patients with diabetes mellitus (Part 2).**
T. Forst, September 13, 2015
147. **The islet of Langerhans - a pathophysiological approach in the treatment of patients with diabetes mellitus (Part 1).**
T. Forst, September 4, 2015
148. **Assessing normality of clinical trial data for statistical analysis.**
A. Fischer, August 19, 2015
149. **Improved automated glucose clamps with clamp.art®.**
C. Benesch, August 11, 2015
150. **Your blood glucose meter might not be sufficiently accurate!**
E. Zijlstra, August 7, 2015
151. **Diabetic and hepatic encephalopathy: similarities, synergies and differences.**
F. Schliess, July 30, 2015
152. **What are glucose clamps and why do we need them?**
U. Hövelmann, July 20, 2015
153. **Great progress in development of an artificial pancreas – the EU-funded AP@home project.**
C. Benesch, July 9, 2015
154. **Are you ready? Update on new EU clinical trial regulations.**
G. Andersen, June 29, 2015
155. **Hepatosselective insulin analogues-a dream may become reality?**
U. Hövelmann, June 23, 2015
156. **Diabetes patients get a voice: patients will change research priorities.**
S. Arnolds, June 3, 2015
157. **Pathways of diabetes: beta cell dysfunction and insulin signaling.**
T. Forst, May 26, 2015
158. **Personalisation in diabetes: a clinical CRO's perspective.**
F. Schliess, May 20, 2015

159. **Lipohypertrophy - The ugly side of insulin injection practice.**
S. Famulla, May 6, 2015
160. **Are you ready for 2016? The new clinical trial regulation EU 536/2014 is coming.**
G. Andersen, April 28, 2015
161. **On the way to a standardized glucose clamp quality control.**
S. Arnolds, April 13, 2015
162. **For healthy living and active ageing: Profil has joined EIT Health.**
F. Schliess, April 7, 2015
163. **New treatments in diabetes mellitus – shifting the paradigm?**
T. Forst, March 31, 2015
164. **Are oral insulins becoming reality?**
L. Bochmann, March 23, 2015
165. **Over-the-counter cough suppressant for diabetes treatment?**
F. Schliess, March 16, 2015

Newspaper Articles (Selection)

166. **Technisches Closed-Loop-System.**
Insuliner, December 1, 2015
167. **Typ 1-Diabetes: künstliche Betazellen überzeugen in ambulanten Praxistests.**
News Deutsches Ärzteblatt, November 16, 2015
168. **Mit dem Smartphone im Kampf gegen Diabetes.**
Neuss Grevenbroicher Zeitung, October 17, 2015



From left to right: Dr Sybille Dellweg (Research Physician, Profil Neuss), trial participant, Dr Carsten Benesch (Director Technical Development, Profil Neuss), trial participant, Dr Sabine Arnolds (Director Research & Development, Profil Neuss)

169. **Studie mit künstlicher Bauchspeicheldrüse: zwölf Wochen ein (fast) normales Leben.**
Sonntag-Morgenmagazin für Universitätsstadt Gießen, October 1, 2015
170. **Diabetesforschung: Helfen Sie mit!**
Odenwälder Lokalblick, October 1, 2015
171. **Hustensaft hilft Diabetikern.**
Der Diabetologe. April 24, 2015
172. **Profil forscht seit 15 Jahren für ein besseres Leben mit Diabetes.**
Gross-Zimmerner Lokal Anzeiger, January 20, 2015